Table 6.

Differences between tofacitinib and abrocitinib[43]

	Tofacitnib	Abrocitnib
Generation	First-generation JAK inhibitor, non-selective	Second-generation JAK inhibitor, selective
Mechanism of action	JAK 1/3 inhibitor	JAK 1 inhibitor
Approval in AD	Off-label use in AD status in respect to the US FDA	US-FDA-approved in moderate-to-severe AD (year/age group)
Laboratory side effects	Neutropenia, lymphocytopenia Liver enzyme elevations Elevations in lipids	Thrombocytopenia, lymphocytopenia Elevations in lipids
Primary metabolizing enzyme	CYP3A4	CYP2C19 and CYP2C9
Primary clearance mechanism	Hepatic metabolism	Urinary excretion
Renal impairment	Mild-moderate: no dose adjustment Severe: half the recommended dose	Mild: no dose adjustment Moderate: 50 or 100 mg QD Severe: 50 mg QD
Hepatic impairment	Mild (Child-Pugh A): No dose adjustment Moderate (Child-Pugh B): Half the recommended dose Severe: Contraindicated	Mild-moderate (Child-Pugh A/B): No dose adjustment Severe (Child-Pugh C): Contraindicated